title: Cost-effectiveness of a smoking cessation program after myocardial infarction.
abstract: OBJECTIVE
  The purpose of this study was to evaluate the cost-effectiveness of a smoking cessation program initiated after acute myocardial infarction.
  
  
  BACKGROUND
  The value of allocating health care resources to smoking cessation programs after myocardial infarction has not been compared with the value of other currently accepted interventions.
  
  
  METHODS
  A model was developed to examine the cost-effectiveness of a recently reported smoking cessation program after an acute myocardial infarction. The cost was estimated by considering the resources necessary to implement the program, and the effectiveness was expressed as discounted years of life saved. Years of life saved were estimated by modeling life expectancy using a single declining exponential approximation of life expectancy based on data from published reports.
  
  
  RESULTS
  The cost-effectiveness of the nurse-managed smoking cessation program was estimated to be $220/year of life saved. In a one-way sensitivity analysis, the cost-effectiveness of the program remained < $20,000/year of life saved if the program decreased the smoking rate by only 3/1,000 smokers (baseline assumption 26/100 smokers), or if the program cost as much as $8,840/smoker (baseline assumption $100). In a two-way sensitivity analysis, even if the cost of the program were as high as $2,000/participant, the cost-effectiveness of the program would be < $10,000/year of life saved so long as the program helped an additional 12 smokers quit for every 100 enrolled.
  
  
  CONCLUSIONS
  Over a wide range of estimates of costs and effectiveness, a nurse-managed smoking cessation program after acute myocardial infarction is an extremely cost-effective intervention. This program is more cost-effective than beta-adrenergic antagonist therapy after myocardial infarction.
authors.affiliation: Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, CT 06510.
authors.forename: H M
authors.initials: HM
authors.lastname: Krumholz
authors.forename: B J
authors.initials: BJ
authors.lastname: Cohen
authors.forename: J
authors.initials: J
authors.lastname: Tsevat
authors.forename: R C
authors.initials: RC
authors.lastname: Pasternak
authors.forename: M C
authors.initials: MC
authors.lastname: Weinstein
mesh_terms: D000704:Analysis of Variance; D001900:Boston; D003362:Cost-Benefit Analysis; D006293:Health Promotion / Q000191:economics*; D006760:Hospitalization; D006801:Humans; D008017:Life Expectancy; D009203:Myocardial Infarction / Q000401:mortality; D009738:Nursing Service, Hospital / Q000191:economics*; D012680:Sensitivity and Specificity; D016540:Smoking Cessation / Q000191:economics*; D016019:Survival Analysis; D026712:Value of Life